Development of Inhibitors Against SARS CoV-2 NSP16 Methyltransferase
Document text
Principal Investigator: HONGMIN LI Organization: LYCHEE BIOSCIENCE LLC Fiscal Year: 2024 Award: $299,985 Funding agency: National Institute of Allergy and Infectious Diseases Abstract: The recent outbreak of SARS-CoV-2 has caused severe economical and humanitarian loss worldwide after it first emergence in Wuhan, China in 2019. The genetic material of this virus is comprised of enveloped, positive- sense, single-stranded RNA. SARS-CoV-2 genome is evolutionary related to the beta coronavirus SARS-CoV causing the previous outbreak in 2003. Currently several vaccines have been launched but targeted therapy to control viral replication and propagation remains limited. In order to rapidly innovate effective medications for clinical curing of this viral infection, we propose to develop new therapeutic agents against COVID-19. We aim to target the nonstructural protein 16 (Nsp16) of SARS-CoV-2, the ribose 2′-O-methyltransferase enzyme (2′-O- MTase) that is responsible for the formation of viral RNA cap-1 structure. The Nsp16 MTase requires the Nsp10 adaptor protein as a co-factor for its enzyme function. The methylation of viral RNA by the Nsp16/Nsp10 complex is critical for both viral replication and viral evasion by host immune recognition. Thus, inhibitors targeting the viral RNA 5’-capping pathways are ideal for controlling and eliminating the virulence of SARS-CoV-2. In this project, we will perform fluorescence polarization (FP)-based high throughput screening (HTS) of small molecule compound libraries using innovative fluorescent analogs of SAM, the methyl donor. We will follow up with several functional MTase assays including HTRF and 32P-labeled substrates to confirm the identified inhibitory activity of selected novel drug-like molecules against the Nsp16/Nsp10 MTase complex of SARS-CoV-2. Validated Nsp16/Nsp10 2’-O-MTase inhibitors will be tested for antiviral activity against SARS-CoV-2. Medicinal optimization of promising candidates will be carried out. Finally, we will use in vivo animal models to investigate the antiviral efficacy of the most potent candidate. The accomplishment of this drug discovery project is to generate a novel avenue of experimental therapy against the existential COVID-19 pandemic via inhibiting the 5’-capping pathways of the coronavirus. Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><5' Capped RNA><5' mRNA Cap Structure><Active Follow-up><Acute Nasopharyngitis><Adaptor Protein><Adaptor Protein Gene><Adaptor Signaling Protein><Adaptor Signaling Protein Gene><Ademetionine><AdoMet><Alpha Virus><Animal Model><Animal Models and Related Studies><Anti-viral Agents><Anti-viral Therapy><Assay><Binding><Binding Sites><Bioassay><Biochemical><Biological Assay><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 genome><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 outbreak><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 virus><COVID-19 virus genome><COVID-19 virus infection><COVID-19 years><COVID19 genome><COVID19 infection><COVID19 outbreak><COVID19 virus><COVID19 virus genome><CV-19><Canine Species><Canis familiaris><Cell-Mediated Cytolysis><Cell-Mediated Lympholysis><Cellular Assay><Cellular Cytotoxicity><Cessation of life><Chemicals><China><Clinical><CoV emergence><CoV-2><CoV2><Combining Site><Common Cold><Complex><Coronaviridae><Coronavirus><Coronavirus Infectious Disease 2019><D-Ribose><Death><Development><Disease><Disease Outbreaks><Disorder><Dogs><Dogs Mammals><Drug Kinetics><Drugs><EBOV><EC 2.1.1><Ebola virus><Ebola-like Viruses><Effectiveness><Enzyme Antagonist><Enzyme Gene><Enzyme Inhibitor><Enzyme Inhibitor Agent><Enzyme Inhibitor Drugs><Enzymes><Experimental Therapies><FDA approved><FRET><Filoviridae><Filovirus><Flavivirus><Fluorescence><Fluorescence Polarization><Fluorescence Resonance Energy Transfer><Funding><Förster Resonance Energy Transfer><GS-5734><Genetic Materials><Group A Arboviruses><Group B Arbovirus><Healthcare><Henipavirus><High Throughput Assay><Human><Immune><Immune system><Immunes><Infection><Influenza Virus><Investigational Therapies><Investigational Treatments><Knowledge><Label><Lead><Learning><Libraries><Lymphocyte Cytotoxicity><Lymphocytotoxicity><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Mainland China><Medication><Medicine><Methylation><Methyltransferase><Microcephaly><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle East Respiratory Virus><Middle East Respiratory coronavirus><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modern Man><Molecular Interaction><NS Proteins><Non-Polyadenylated RNA><Non-structural Protein><Nonstructural Protein><Orthoflavivirus><Outbreaks><Pathway interactions><Pb element><Pharmaceutical Preparations><Pharmacokinetics><Population><Position><Positioning Attribute><Poxviridae><Poxviruses><Prevention><Property><Prophylactic treatment><Prophylaxis><Public Health><RNA><RNA Caps><RNA Gene Products><Reactive Site><Research><Research Resources><Resources><Ribonucleic Acid><Ribose><S-Adenosylhomocysteine><S-Adenosylmethionine><S-adenosyl methionine><S-adenosyl-methionine><SAMe><SARS><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS coronavirus disease><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV disease><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 genome><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV2><SARS-CoV2 genome><SARS-CoV2 infection><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Structure><Testing><Therapeutic><Therapeutic Agents><Vaccination><Vaccines><Variant><Variation><Veklury><Viral><Viral Activity><Viral Diseases><Viral Function><Viral Genome><Viral Nonstructural Proteins><Viral Physiology><Virulence><Virus><Virus Diseases><Virus Replication><Work><Wuhan coronavirus><ZIKV><Zika Virus><active followup><adapter protein><analog><anti-viral compound><anti-viral drugs><anti-viral efficacy><anti-viral medication><anti-viral therapeutic><anti-virals><beta CoV><beta coronavirus><betaCoV><betacoronavirus><candidate validation><canine><cell assay><cell mediated cytotoxicity><cofactor><combat><companion animal><companion cat><companion dog><companion pet><corona virus><corona virus emergence><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 genome><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 virus><coronavirus disease 2019 virus genome><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 outbreak><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><cross-species spillover><cross-species transmission><design><designing><developmental><domestic dog><drug candidate><drug development><drug discovery><drug-like chemical><drug-like compound><drug-like molecule><drug/agent><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><experimental therapeutic agents><experimental therapeutics><follow up><follow-up><followed up><followup><future outbreak><future pandemic><hCoV19><health care><heavy metal Pb><heavy metal lead><hesitant to vaccination><high throughput screening><host jump><host switching><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><influenzavirus><inhibitor><innovate><innovation><innovative><interest><interspecies transmission><methylase><micrencephaly><microencephaly><model of animal><molnupiravir><mortality><mouse model><murine model><nCoV><nCoV2><new CoV><new corona virus><new coronavirus><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><next outbreak><next pandemic><nirmatrelvir><novel><novel CoV><novel corona virus><novel coronavirus><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><outbreak in the future><outbreak of SARS-CoV-2><pandemic><pandemic concern><pandemic disease><pandemic potential><pandemic risk><pandemic threat><past outbreak><pathway><pharmacologic><pox virus><previous outbreak><prior outbreak><rational design><remdesivir><s-adenosyl-l-methionine><screening><screenings><severe acute respiratory syndrome coronavirus 2 genome><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome-CoV><small molecular inhibitor><small molecule><small molecule inhibitor><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tool><transmethylase><transmission across species><transmission between species><transmitted across species><transmitted between species><transmitted cross-species><vaccination hesitancy><vaccine hesitancy><vaccine hesitant><viral RNA><viral infection><viral infectious disease treatment><viral multiplication><viral replication><virus RNA><virus genome><virus infection><virus multiplication><virus-induced disease><zikav><β CoV><β coronavirus><βCoV>